INTRODUCTION
Primary Sjogren's syndrome (pSS) is a chronic autoimmune disorder with polyclonal B cell activation and lymphocytic infiltration of the exocrine glands which characterized by dry eyes and a dry mouth. The estimated annual incidence of pSS is 4 to 6 per 100,000 inhabitants according to population-based studies. [1] [2] [3] [4] Studies have shown that patients with pSS have higher incidence of non-Hodgkin's lymphoma (NHL) compared with general population with the standardized incidence ratio (SIR) ranged from 8.7 (95% CI 4.3 to 15.5) to 48.1 (95% CI 20.7 to 94.8). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] However, because of small number of patients observed in previous studies, little is known whether patients with pSS also have high risk in developing cancers other than NHL.
The Taiwan National Health Insurance (NHI) program is a mandatory, compulsory, single-payer health insurance system in which all citizens are obliged to participate. The NHI program was implemented in 1995 and covered 99.5% of the population of Taiwan by the end of 2008. 15 The NHI Research Database has been released to researchers in an electronically encrypted form since 1999. Because of large sample size and high quality in cancer related diagnosis in this claims data, this dataset provided good opportunity to estimate incidence of cancer among patients with
Helicobacter pylori infection, 16, 17 diabetes mellitus 18, 19 and autoimmune diseases. [20] [21] [22] [23] We therefore aimed in this study to compare the incidence of cancer of various site among pSS patients with general population in Taiwan using Taiwan NHI claims data.
PATIENTS AND METHODS

Data sources
The Catastrophe Illness File of NHI claims data was used for this study. To avoid financial catastrophe for families coping with major injuries/illnesses, the NHI specifies 31 categories of catastrophic illness (e.g., cancers, hemophilia, autoimmune diseases, chronic renal failure, etc.)
that are exempt from co-payment. The attending physician of patient diagnosed as falling into one of these categories of catastrophic illness under the Department of Health guidelines can submit related information to complete an application for a catastrophic illness certificate (CIC).
Applications are formally reviewed by committee, and if approved, patients are then exempted from co-payment.
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Cohort of patients with pSS
In this study, the cohort of patients with pSS confined to those approved CIC for pSS aged ≧25
years between 2000 and 2008. To get an CIC for pSS, the attending physician of the patient is required to provide relevant clinical and laboratory information as part of the application for review, and the review committee will assess applications according to the criteria of the American-European Consensus Group for pSS. 25 We excluded patients with both a CIC for pSS and a CIC for any other autoimmune disease, such as systematic lupus erythematosus, rheumatoid arthritis, other connective tissue diseases, etc., who should instead be classified as having secondary Sjӧgren syndrome. Patients who had CIC for cancer before having CIC for pSS were also excluded.
Identification of cancer
Cancer is one of 31 categories of catastrophic illness defined by NHI. To approve for CIC for cancer, the attending physician should provide pathology evidence and imaging studies supporting the diagnosis of cancer which including radiographs, bone scans, computed tomography, or magnetic resonance imaging scans. The records are reviewed by a committee and only patients who meet the criteria for the diagnoses are issued CIC. The ICD-9-CM codes were used to define cancer of various sites.
Statistical analysis RESULTS
A total of 7852 patients (6911 females and 941 males) with pSS aged ≧25 years were identified between 2000 and 2008. The average follow-up years were 3.5 years. The mean age (SD) at time of approving CIC for pSS was 54 (14) years and most patients were in 45-64 years of age (Table 1) .
A total of 227 (2.9%) patients with pSS were diagnosed of having cancer after the approval of CIC for pSS during the observation period of 27,246 person-years. The incidence of cancer among patients with pSS increased with age and male patients had higher incidence than female patients ( Table 2 ). Only patients with pSS aged 25-44 years had significantly higher SIR ( Table 3 ). The longer the years the patients were followed the lower the risk the patients been identified with cancer (Table 4) . Table 5 presents SIR and 95% CI for cancer of various sites with number of incident cancer at least three. Female patients with pSS had higher risk of NHL, multiple myeloma and thyroid gland cancer and lower risk of colon cancer. On the contrast, male patients with pSS did not have higher risk in developing cancer of particular site.
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DISCUSSION
The findings of this study suggest that incidence of cancer among patients with pSS increased with age and male patients had higher incidence than female patients. However, compared with same sex-age group, only patients with pSS aged 25-44 years had higher risk of cancer. Consistent with previous studies, patients with pSS in this study also had higher risk in developing NHL. With regard to cancers other than NHL, this study found that female patients with pSS also had higher risk of multiple myeloma and thyroid gland cancer and lower risk of colon cancer.
One of the strengths of this study was that this was the first study using nationwide population cohort and having the largest sample size compared with previous studies which allowed us to calculate incidence of cancer among patients with pSS by sex-age group and to estimate risk of cancer other than NHL.
However, several limitations existed in this study. First, there were no laboratory data availabe in claims data we thus could not analyze detail risk factors in developing cancer. Second, we included only patients with CIC for pSS, some patients with pSS diagnosis in ambulatory care
claims data without CIC for pSS were not included in the cohort. Third, in the same token, some patients with cancer might not apply for CIC for cancer, which would not be identified in this study.
Fourth, the average follow-up years (3.5 years) in this study was relatively short. Fifth, unlike the study of Lazarus et al 12 which included cancer either before or after diagnosis of pSS, we excluded those having cancer before date of getting CIC for pSS. In other words, some patients who had pSS and then carcinogenesis changes long before applying CIC for pSS were excluded from this study.
In consideration of above-mentioned limitations, the risk of cancer was underestimated in this study.
Consistent with previous studies, we also confirmed that patients with pSS had higher risk of having NHL. However, the SIR for NHL in this study is lower than previous studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The main reason for underestimation of SIR for NHL was the short follow-up years observed in this study.
Similar to study of Zhang et al., 14 we also found that patients with pSS had higher risk of having thymus cancer in this study. We did not present the SIR for thymus cancer in Table 5 because only two thymus cancers were identified. This is the first study to suggest that patients with pSS had higher risk for multiple myeloma and thyroid cancer. No study, to best of our knowledge, ever proposed possible associations between pSS and multiple myeloma and thyroid cancer. 是否要再加幾句話？不加也可以，流病研究不用太細 說明 As pSS, thymus cancer and thyroid cancer all involve glands, maybe there are some mechanisms correlate pSS and glandular cancers.
One accidental finding of this study was that patients with pSS had lower risk of having colon cancer. Similar finding was found among patients with rheumatoid arthritis with SIR of 0.94 (95% CI 0.93-0.96) in Taiwan. 20 One possible explanation was that many patients with pSS might also have myoglagia (引用文獻) and regularly use NSAID, (引用文獻) which result in lower risk of colon cancer.
Further studies are needed to confirm this hypothesis.
In conclusion, according to the findings of this study, patients with pSS overall did not have higher risk of cancer, only patients with pSS aged 25-44 years had increase risk of cancer.
Physicians caring for patients with pSS should screen not only NHL, a well known cancer with higher risk among patients with pSS, but also multiple myeloma and thyroid gland cancer. Further studies are needed to investigate possible mechanisms associate with pSS and glandular cancers. 
